Puma Biotechnology, Inc. — FY 2014 Form 10-K
Reporting period: Year ended December 31, 2014; filed March 2, 2015. This annual filing also provides unaudited quarterly results. Puma is a clinical-stage oncology biopharmaceutical company with no approved products or product revenue. Its lead candidate is neratinib (PB272), licensed from Pfizer.
Financial performance and position
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $122.9 million | $45.0 million |
| General and administrative expense | $19.4 million | $9.8 million |
| Operating loss | $142.3 million | $54.8 million |
| Net loss | $142.0 million ($4.73 per share) | $54.7 million ($1.90 per share) |
| Cash used in operating activities | $77.2 million | $55.0 million |
| Cash and cash equivalents | $38.5 million | $43.0 million |
| Marketable securities | $102.8 million | $40.9 million |
| Total assets / total liabilities | $162.8 million / $45.7 million | $104.4 million / $20.4 million |
With no revenue, profit, or meaningful operating margin, traditional revenue-margin comparisons are not applicable. No borrowings or financial debt are reported in the provided balance sheet; liabilities are primarily payables, accrued expenses, and deferred rent. Year-end cash plus marketable securities totaled $141.3 million. Stock-based compensation was $39.2 million, a substantial noncash component of expenses. The filing reports no off-balance-sheet arrangements.
Material changes and notable items
- Net loss increased to $142.0 million from $54.7 million, while operating cash use rose to $77.2 million from $55.0 million. R&D expense increased 173%, mainly reflecting responsibility for Pfizer-originated legacy trial costs beginning in 2014, expanding company-sponsored trials, and higher stock-based compensation.
- G&A expense nearly doubled, primarily due to higher stock-based compensation, payroll, professional fees, and facilities. The 2014 net loss also includes $39.2 million in stock-based compensation; the filing presents a non-GAAP adjusted net loss of $102.8 million, which excludes this expense.
- In February 2014, Puma raised approximately $129.4 million net from a common-stock offering. A subsequent January 2015 offering raised approximately $205.0 million net. Year-end shares outstanding were 30.5 million; the January offering increased shares by 1.15 million.
- Accrued expenses rose to $29.4 million, including $16.4 million of payroll taxes withheld on employee option exercises and paid in January 2015. Accounts payable were $15.0 million.
Clinical outlook, management commentary, and risks
- Development milestones: Management planned to present ExteNET Phase III results in mid-2015 and file for approval of neratinib in the extended-adjuvant setting in Q1 2016. The third-line metastatic breast cancer Phase III trial was ongoing. The filing anticipated results from several other trials during 2015. These were plans, not guaranteed outcomes.
- Trial results: ExteNET top-line results showed a statistically significant improvement in disease-free survival versus placebo (hazard ratio 0.67; p=0.0046). In the NEfERTT Phase II trial, first-line progression-free survival was similar between neratinib and trastuzumab combinations (16.6 versus 16.7 months); reported CNS metastases incidence was lower with neratinib (7.4% versus 15.6%; p=0.006). Neither result by itself establishes regulatory approval or commercial success.
- Spending and liquidity outlook: Management estimated R&D spending of $115–130 million and G&A spending of $10–12 million over the next 12 months, both excluding stock-based compensation. It expected year-end resources plus the January 2015 offering proceeds to fund operations into 2016 and beyond, while noting that additional capital might be needed and was not assured.
- Key risks: Puma remains dependent on clinical and regulatory success for neratinib, patient enrollment, third-party CROs and manufacturers, and its Pfizer license. Neratinib-associated diarrhea is a significant safety concern; the filing describes efforts to reduce it with prophylactic loperamide. Other risks include competition, reimbursement and pricing uncertainty, patent protection, potential dilution from future financing, and substantial ongoing losses.
- Pfizer license: A July 2014 amendment made Puma responsible for legacy-trial expenses incurred or accrued after December 31, 2013 and changed future royalties to a fixed low-to-mid-teens rate. The agreement also provides for up to $187.5 million in milestone payments if all milestones are achieved. The filing lists $16.5 million of potential CRO milestone payments, payable only if milestones are reached.
Investor verification points
- Review the full audited statements and notes, especially the composition and maturity of marketable securities, accrued trial costs, and cash-burn assumptions.
- Track actual spending against management’s forward estimates and assess how long the post-offering cash runway supports planned trials.
- Verify subsequent ExteNET and other trial data, regulatory submissions, FDA decisions, and whether stated timelines were met.
- Assess tolerability and diarrhea-management data, including whether prophylactic loperamide results are sustained in larger trials.
- Review the Pfizer license’s royalty, milestone, and transfer provisions, plus potential stock dilution from equity awards and future financing.